Pomerantz Law Firm Alerts Investors on Lawsuit Against Rocket Pharmaceuticals Over Securities Fraud

Investor Alert: Class Action Lawsuit Against Rocket Pharmaceuticals

Pomerantz LLP has announced the initiation of a class action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) which could significantly impact investors who have suffered losses in their financial engagements with the company. Those concerned about their investments are encouraged to reach out to Danielle Peyton at [email protected] or call 646-581-9980, extending to 888-4-POMLAW, toll-free. Investors are invited to provide their contact details and the number of shares purchased via email for follow-ups.

The lawsuit stems from allegations that Rocket and some of its executives may have engaged in securities fraud and other illegitimate business practices. As a result, this could have serious implications for stockholders and those investing in Rocket during the specified class period.

Potential claimants have until August 11, 2025, to submit requests to the court to be appointed as Lead Plaintiff for the class. Detailed information on the complaint is accessible at www.pomerantzlaw.com.

In May 2025, Rocket made a significant press announcement regarding RP-A501, its new gene therapy targeting Danon disease. Unfortunately, a patient involved in its Phase 2 trial experienced a Serious Adverse Event (SAE) due to complications arising from capillary leak syndrome. Following this incident, the company voluntarily halted further dosing in the trial. Subsequently, the FDA imposed a clinical hold on the trial to further evaluate the situation, emphasizing the gravity of the circumstances. Sadly, the patient in question later passed away due to acute systemic infection, amplifying concerns regarding the therapy’s safety and efficacy.

Following this revelation, Rocket’s stock saw a considerable decline, plunging by $3.94 per share or 62.84%, closing at $2.33 per share on the same day. The alarming drop reflects investors’ response to the disclosure and raises serious questions on the company’s operational integrity.

Pomerantz LLP has built its reputation as a leading law firm specializing in corporate, securities, and antitrust class actions. With offices in major cities including New York, Chicago, and internationally in London, Paris, and Tel Aviv, the firm has a long history of championing the rights of investors against corporate misconduct and ensuring transparency in financial dealings. Founded over 85 years ago by Abraham L. Pomerantz, often regarded as the pioneer of the class action landscape, Pomerantz continues to pursue justice for victims of fraud.

As the case develops, affected investors are urged to stay informed and consider the legal options available to ensure their voices are heard. For updates and more details on how to engage with this class action, visit Pomerantz’s official site. Investors must keep abreast of the situation as the legal proceedings unfold, which could have lasting effects on both the company and its stakeholders. Remember, this lawsuit is not just about Rocket Pharmaceuticals, but a broader issue of accountability in the corporate sector, making it essential for all investors to remain vigilant.